🌿 Apium Graveolens Clinical Report • March 2026
Celery Seed Extract: Standardized Antihypertensive Efficacy
An evidence-based analysis of standardized celery seed extract (8.8% volatile oils) and its multi-pathway impact on systolic and diastolic blood pressure through calcium channel blockade, NO-mediated vasodilation, and potassium-sparing diuresis.
Celery Seed Extract: Standardized Antihypertensive Efficacy
Clinical Data Visualization • Mt. Angel Vitamins • March 2026
Phytochemical Composition
The therapeutic value of celery seed extract depends on its active constituents. Standardization ensures consistent delivery of 3-n-butylphthalide (3nB) and other volatile oils responsible for vasodilatory effects.
Clinical Efficacy Over Time
Progressive reduction in systolic and diastolic blood pressure over a 6-week supplementation protocol. Significant changes are typically observed beginning in week 3.
Dose-Response Relationship
Analyzing individual patient data reveals a clear relationship between dosage and systolic BP reduction. Diminishing returns beyond 200mg/day identify 150mg as a highly efficient clinical target.
Mechanism of Action
The primary active compound 3nB induces vasodilation through specific biochemical pathways, primarily acting as a mild diuretic and calcium channel modulator.
Comparative Cardiometabolic Outcomes
Standardized mean reductions across key cardiometabolic markers from the 2025 meta-analysis of randomized controlled trials.
Safety & Tolerability
Clinical trials consistently demonstrate the extract does not cause hepatotoxicity or renal damage. Adverse events are infrequent, entirely mild, and self-resolving—significantly safer than synthetic NSAID or diuretic therapies.
Clinical Recommendations
Multi-Pathway Efficacy: The 8.8% volatile oil extract simultaneously executes calcium channel blockade, NO-mediated vasodilation, potassium-sparing diuresis, and autonomic regulation for comprehensive BP control.
Meta-Analytically Validated: The 2025 systematic review of 511 participants confirms statistically significant reductions in systolic BP (SMD −1.0), diastolic BP (SMD −0.93), and triglycerides (SMD −1.18).
Exceptional Safety: Zero hepatotoxicity or renal damage across all trials. Adverse events are mild, self-resolving, and statistically equivalent to placebo—ideal for long-term cardiovascular management.
Data visualizations are based on published clinical trial results. For educational purposes. This content does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.